Amble vs Vaylen
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Amble
Best for mainstream telehealth GLP-1 accessStarting at $179/mo
Vaylen
Best for GLP-1-focused care with oral and injectable options across all 50 statesStarting at $179/mo
Side-by-Side Comparison
| Feature | Amble | Vaylen |
|---|---|---|
| Overall Score | 7.4/10 | ✓7.6/10 |
| Starting Price | $179/mo | $179/mo |
| Editorial Rating | 3.7 ★ /5 | ✓3.8 ★ /5 |
| Features | 3 features | ✓7 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Amble
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Vaylen
Pros
- ✓Pure GLP-1 specialist — not a multi-category telehealth platform
- ✓All 50 states coverage with licensed clinicians
- ✓Both compounded and brand-name options (Ozempic, Wegovy, Zepbound)
- ✓Oral GLP-1 option (compounded dissolvable tablets) for needle-averse patients
- ✓LegitScript certified
- ✓Transparent pricing — no hidden costs, no insurance required
- ✓Continuous coaching and lab support included
Cons
- ✗Compounded semaglutide at $179/mo is mid-range (not the cheapest)
- ✗Brand-name options at near-retail pricing ($997–$1,350/mo)
Our Verdict
Vaylen edges out Amble with a higher overall score of 7.6/10 and is particularly strong for GLP-1-focused care with oral and injectable options across all 50 states. Amble remains a solid alternative, especially if you're looking for mainstream telehealth GLP-1 access.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.